CSF1R-IN-2 NEW
| Price | $34 | $77 | $127 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-21 |
Product Details
| Product Name: CSF1R-IN-2 | CAS No.: 2271119-26-5 |
| Purity: 99.71% | Supply Ability: 10g |
| Release date: 2026/04/21 |
Product Introduction
Bioactivity
| Name | CSF1R-IN-2 |
| Description | CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively). |
| In vitro | The suppression of MET autophosphorylation as well as the downstream STAT3 caused by CSF1R-IN-2, ERK and AKT phosphorylation at IC50 values of around 1-3 nM in SNU-5 and MKN-45 cell lines. |
| In vivo | In mice, CSF1R-IN-2 (p.o., BID, 13 days) treatment results in an 85% tumor regression, and no bodyweight loss is observed after 21 days of treatment. In SCID/Beige mice. CSF1R-IN-2 (p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID, and 15 mg/kg, BID, respectively. In mice, CSF1R-IN-2 inhibits MET activity in MKN-45 tumors following oral administration. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (61.06 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2 mg/mL (4.88 mM), Sonication is recommended. |
| Keywords | SRC | MET | Inhibitor | inhibit | HGFR | CSF1R-IN-2 | CSF-1R-IN-2 | CSF1RIN2 | CSF1R IN 2 | CSF-1R | CSF1R | CSF-1 receptor | colony stimulating factor 1 receptor | c-Met/HGFR | cMet/HGFR | c-Met | cMet | c-FMS | cFms |
| Inhibitors Related | (S)-Afatinib | Vemurafenib | PLX5622 | Decanoic Acid | Afatinib Dimaleate | Dasatinib | Ibrutinib | Pexidartinib | Crizotinib | iHCK-37 | Afatinib | Bacitracin Zinc |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-29 | ||
| $95.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-26 | |
|
VIP1Y
|
ACROBiosystems
|
2026-07-02 | ||
| $34.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY